½ÃÀ庸°í¼­
»óǰÄÚµå
1552620

FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Fluorescence In Situ Hybridization Imaging Systems Market Size, Share & Trends Analysis Report By Product (Instruments), By Application (Cancer Diagnosis), By End Use, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 8.4%ÀÇ CAGR·Î È®´ëµÇ¾î 2030³â¿¡´Â 21¾ï 4,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ü¿ÜÁø´Ü °ü·Ã R&D ÅõÀÚ Áõ°¡°¡ FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, À¯·´ ü¿ÜÁø´Ü ½ÃÀåÀÇ °³Ã´°ú ¼ºÀåÀ» Áß½ÃÇÏ´Â À¯·´Áø´ÜÁ¦Á¶¾÷üÇùȸ¿Í °°Àº Á¤ºÎ±â°üÀÇ Á¸Àçµµ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, FISH À̹Ì¡ ½Ã½ºÅÛÀº º´¿øÃ¼³ª ¹ÚÅ׸®¾Æ¿¡ ÀÇÇÑ °ÍÀ¸·Î ÀǽɵǴ Áúº´À» ÆÇ´ÜÇϱâ À§ÇÑ Áø´Ü¿ëÀ¸·Îµµ °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. ¸²ÇÁÁ¾, °íÇü Á¾¾ç, ¹éÇ÷º´, ÀÚÆóÁõ ¹× ±âŸ ¹ß´Þ ÁõÈıº°ú °°Àº À¯Àü¼º ÁúȯÀÇ ¹ß»ý·ü Áõ°¡µµ äÅÃÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °¨¿°¼º Áúȯ °Ë»ç¿¡¼­ Åõ½Ã ÀåÄ¡, Çö¹Ì°æ, Á¶¸í±â, CCD Ä«¸Þ¶óÀÇ º¸±ÞÀÌ È®´ëµÇ¸é¼­ ÀÌµé ½Ã½ºÅÛÀÇ ¼ºÀå ±âȸ°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¾Ï, À¯ÀüÀÚ ÀÌ»ó µî ¿°»öü ÀÌ»ó ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í °³¹ßµµ»ó±¹ÀÇ ¹ÌÃæÁ· Áø´Ü ¹× ÀÓ»ó ¼ö¿ä Áõ°¡°¡ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, Áúº´ °ËÁõÀ» À§ÇÑ ½Å¼ÓÇÏ°í ¹Î°¨Çϸç Á¤È®ÇÑ Áø´Ü ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÎ½Ä Áõ°¡, ÀÇ·áºñ ÁöÃâ Áõ°¡, »õ·Î¿î ¿µ»ó ½Ã½ºÅÛ °³¹ßÀ» À§ÇÑ ±¤¹üÀ§ÇÑ ¿¬±¸ °³¹ßµµ ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå º¸°í¼­ - ÇÏÀ̶óÀÌÆ®

  • FISH À̹Ì¡ ¼­ºñ½º´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ÇöÀç ¾Ï Áø´Ü¿¡¼­ FISH À̹Ì¡ÀÇ ½ÃÀå ħÅõÀ²ÀÌ ¸Å¿ì ³ô±â ¶§¹®¿¡ Áø´Ü ½ÇÇè½Ç ºÎ¹®ÀÌ ´õ Å« ¼öÀÍÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
  • ¾Ï ¹ß»ý·üÀÇ Áõ°¡·Î ÀÎÇØ ¾Ï Áø´ÜÀÌ °¡Àå Å« ¸ÅÃâ ºñÁßÀ» Â÷ÁöÇϸç FISH À̹Ì¡ ½Ã½ºÅÛ Ã¤Åÿ¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.
  • ÃÖÁ¾ »ç¿ë ºÐ¾ß Áß µ¿¹ÝÁø´ÜÀº Á¶»ç ¹× Áø´Ü ºÐ¾ßº¸´Ù ´õ ºü¸¥ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
  • ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ÀڱðæºÎ¾Ï Àü¾Ï º´º¯ÀÇ ½Ã°¢È­, ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º À§Çè Æò°¡, ¹éÇ÷º´, °ñ¼öÀÌÇü¼ºÁõÈıº, ´Ù¹ß¼º °ñ¼öÁ¾, ¿°»öü ÀÌ»ó °ËÃâ µî ´Ù¾çÇÑ ÀÓ»ó ¿¬±¸¿¡ ÁÖ·Î »ç¿ëµÇ±â ¶§¹®¿¡ Áø´Ü ½ÇÇè½ÇÀÌ 2016³â¿¡ Áö¹èÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇß½À´Ï´Ù.
  • ºÏ¹Ì°¡ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇϰí Àִµ¥, ÀÌ´Â ÀÌ Áö¿ªÀÇ ¿¬±¸ °³¹ß¿¡¼­ ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀÌ ³Î¸® äÅõǾú±â ¶§¹®ÀÔ´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº Á¦Á¶¾÷ü¿Í Á¤ºÎÀÇ ÅõÀÚ Áõ°¡, »ý¸í°øÇÐ ºÐ¾ßÀÇ Àû±ØÀûÀÎ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê, ¹Ì°³Ã´ ±âȸ°¡ ¸¹±â ¶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ÀÌ »ê¾÷Àº °æÀïÀÌ Ä¡¿­Çϸç, ¼Ò¼öÀÇ ±â¾÷ÀÌ Àüü ¼öÀÍÀÇ ´ëºÎºÐÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. °¡Àå ÁÖ¸ñÇÒ ¸¸ÇÑ ½ÃÀå ÁøÀÔ ±â¾÷À¸·Î´Â Euroclone SpA, TissueGnostics GmbH, Agilent Technologies, Inc, General Electric Company µîÀÌ ÀÖ½À´Ï´Ù. À̵éÀº ¾÷°è¿¡¼­ »ó´çÇÑ Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå ¼Ò°³/°èÅë Àü¸Á
  • ½ÃÀå ±Ô¸ð¿Í ¼ºÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅۺм®
    • Porters ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå : Á¦Ç°º° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®, 2023³â ¹× 2030³â
  • ±â±â
  • ¼Ò¸ðǰ°ú ¾×¼¼¼­¸®
  • ¼­ºñ½º
  • ¼ÒÇÁÆ®¿þ¾î

Á¦5Àå FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ : ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®, 2023³â ¹× 2030³â
  • ¾Ï Áø´Ü
    • ½ÃÀå ¸ÅÃâ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • Æó¾Ï
    • À¯¹æ¾Ï
    • ±âŸ
  • À¯Àü¼º Áúȯ Áø´Ü
    • ½ÃÀå ¸ÅÃâ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
  • ±âŸ
    • ½ÃÀå ¸ÅÃâ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â

Á¦6Àå FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®, 2023³â ¹× 2030³â
  • Áø´Ü °Ë»ç½Ç
    • ½ÃÀå ¸ÅÃâ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
  • ¿¬±¸¡¤Çмú±â°ü
    • ½ÃÀå ¸ÅÃâ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
  • ±âŸ
    • ½ÃÀå ¸ÅÃâ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â

Á¦7Àå FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ Á¡À¯À², Áö¿ªº°, 2023³â ¹× 2030³â
  • ºÏ¹Ì
    • ºÏ¹Ì FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • À¯·´ÀÇ FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ FISH(Fluorescent In Situ Hybridization) À̹Ì¡ ½Ã½ºÅÛ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï »óȲ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
  • ±â¾÷ ºÐ·ù
  • ±â¾÷ È÷Æ®¸Ê ºÐ¼®
  • ±â¾÷ °³¿ä
    • Euroclone SpA
    • TissueGnostics GmbH
    • Agilent Technologies, Inc.
    • Abnova Taiwan Corp
    • BioGenex Laboratories Inc
    • Leica Biosystems Nussloch GmbH
    • Bio-View Ltd
    • Thermo Fisher Scientific, Inc.
    • MetaSystems Probes GmbH
ksm 24.09.23

Fluorescence In Situ Hybridization Imaging Systems Market Growth & Trends:

The global fluorescence in situ hybridization imaging systems market size is expected to reach USD 2.14 billion by 2030, expanding at a CAGR of 8.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing R&D investments pertaining to in vitro diagnostics are expected to drive the Fluorescence In Situ Hybridization (FISH) imaging systems market. The presence of government organizations, such as the European Diagnostic Manufacturers Association that focuses on the development and growth of the in vitro diagnostics market in Europe, is also contributing to growth.

Furthermore, FISH imaging systems are gaining popularity in diagnostics for the determination of suspected diseases caused by pathogens or bacteria. Increasing incidence of genetic diseases, such as lymphoma, solid tumors, leukemia, autism, and other developmental syndromes, is also expected to boost adoption. Growing penetration of fluoroscopy, microscopes, illuminators, and CCD cameras in testing for infectious diseases is expanding growth opportunities for these systems. Increasing prevalence of diseases with chromosomal aberrations, such as cancer and genetic abnormalities, as well as unmet diagnostic & clinical needs in developing countries, is anticipated to drive the market.

Moreover, increasing demand for rapid, sensitive, & accurate diagnostic techniques for validation of diseases, coupled with rising awareness, increase in healthcare expenditure, and extensive R&D for the development of novel imaging systems are also expected to drive growth over the forecast period.

Fluorescence In Situ Hybridization Imaging Systems Market Report Highlights:

  • Instruments held the largest market, whereas FISH imaging services are expected to grow at the fastest rate during the forecast period
  • At present, the market penetration of FISH imaging in cancer diagnostics is very high, hence the diagnostic laboratories segment accounted for larger revenues
  • Cancer diagnosis held the largest revenue share owing to increasing incidence of cancer, thus fueling the adoption of FISH imaging systems
  • Among end-use segments, companion diagnostics is expected to witness faster growth than research and diagnostic segments
  • Diagnostic laboratories held the dominant position in 2016 as these systems are predominantly used in various clinical studies for visualization of precancerous lesions in cervical cancer, assessing the risk of human papillomavirus, and for detection of leukemia, myelodysplastic syndrome, multiple myeloma, & chromosomal abnormalities
  • North America held the largest revenue share owing to extensive adoption of these solutions in research and development across this region
  • Asia Pacific is anticipated to exhibit lucrative CAGR over the forecast period due to the increase in investments by manufacturers & governments, supportive government initiatives in the biotechnology sector, and the presence of a large number of untapped opportunities
  • The industry is highly competitive with a limited number of players holding a majority of the overall revenues. Some of the most notable market participants are Euroclone SpA, TissueGnostics GmbH, Agilent Technologies, Inc., Abnova Taiwan Corp, BioGenex Laboratories Inc., o Bio-View Ltd and General Electric Company. They account for a considerable share of the industry

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Fluorescence In Situ Hybridization Imaging Systems Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Fluorescence In Situ Hybridization Imaging Systems Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Fluorescence In Situ Hybridization Imaging Systems Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Fluorescence In Situ Hybridization Imaging Systems Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Instruments
    • 4.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Microscopes
      • 4.3.2.1. Microscopes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Automated cell analyzers
      • 4.3.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Others
      • 4.3.4.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Consumables & Accessories
    • 4.4.1. Consumables & Accessories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Software
    • 4.6.1. Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Fluorescence In Situ Hybridization Imaging Systems: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Fluorescence In Situ Hybridization Imaging Systems Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Cancer Diagnosis
    • 5.3.1. Cancer Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Lung Cancer
      • 5.3.2.1. Lung Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Breast Cancer
      • 5.3.3.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. Others
      • 5.3.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Genetic Disease Diagnosis
    • 5.4.1. Genetic Disease Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Fluorescence In Situ Hybridization Imaging Systems: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Fluorescence In Situ Hybridization Imaging Systems Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Diagnostic Laboratories
    • 6.3.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Research & Academic Institutes
    • 6.4.1. Research & Academic Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Fluorescence In Situ Hybridization Imaging Systems Market: Regional Estimates & Trend Analysis

  • 7.1. Fluorescence In Situ Hybridization Imaging Systems Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Sweden Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Fluorescence In Situ Hybridization Imaging Systems and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Euroclone SpA
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. TissueGnostics GmbH
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Agilent Technologies, Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Abnova Taiwan Corp
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. BioGenex Laboratories Inc
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Leica Biosystems Nussloch GmbH
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Bio-View Ltd
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Thermo Fisher Scientific, Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. MetaSystems Probes GmbH
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦